Nanjing Delova Drug Patent Portfolio
Nanjing Delova owns 1 orange book drug protected by 1 US patent Given below is the list of Nanjing Delova's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12059423 | Meloxicam composition, pharmaceutical preparation and preparation method and use thereof | 19 Jul, 2040 | Active |
Latest Legal Activities on Nanjing Delova's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Nanjing Delova.
| Activity | Date | Patent Number |
|---|---|---|
| ||
| Email Notification | 13 Aug, 2024 | US12059423 |
| Patent Issue Date Used in PTA Calculation | 13 Aug, 2024 | US12059423 |
| Patent eGrant Notification | 13 Aug, 2024 | US12059423 |
| Recordation of Patent eGrant | 13 Aug, 2024 | US12059423 |
| Mail Patent eGrant Notification | 13 Aug, 2024 | US12059423 |
| Recordation of Patent Grant Mailed | 13 Aug, 2024 | US12059423 |
| Email Notification | 25 Jul, 2024 | US12059423 |
| Issue Notification Mailed | 24 Jul, 2024 | US12059423 |
| Dispatch to FDC | 03 Jul, 2024 | US12059423 |
| Application Is Considered Ready for Issue | 03 Jul, 2024 | US12059423 |
| Issue Fee Payment Verified | 01 Jul, 2024 | US12059423 |
| Issue Fee Payment Received | 01 Jul, 2024 | US12059423 |
| Mail Post Card | 15 May, 2024 | US12059423 |
| Email Notification | 10 May, 2024 | US12059423 |
| Filing Receipt - Replacement | 10 May, 2024 | US12059423 |
Nanjing Delova's Family Patents
Nanjing Delova Drug List
Given below is the complete list of Nanjing Delova's drugs and the patents protecting them.
1. Qamzova
Qamzova is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12059423 | Meloxicam composition, pharmaceutical preparation and preparation method and use thereof |
19 Jul, 2040
(14 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qamzova's drug page